Fig. S1. Proportion of patients with moderate-to-severe psoriasis achieving complete clearance of their nail psoriasis (Nail Psoriasis Severity Index (NAPSI)=0) (observed) at each post-baseline visit up to week 264. Data presented as observed. Symbols in line graphs are offset horizontally to differentiate overlapping data points.

Fig. S2. Mean improvement in overall Nail Psoriasis Severity Index (NAPSI) score (observed) of adult patients with moderate-to-severe psoriasis treated with ixekizumab (IXE) during 264 weeks in patients with baseline nail psoriasis (NAPSI ≥1; N=219; grey) and the subgroup of patients with significant baseline nail psoriasis (NAPSI ≥16 and ≥4 fingernails involved; n=134/219; red). N: number of patients.
Fig. S3. Mean improvement (observed) in overall Nail Psoriasis Severity Index (NAPSI) score (Observed), nail bed (solid line) and nail matrix features (dotted line) of adult patients with moderate-to-severe psoriasis treated with ixekizumab (IXE) during 264 weeks in patients with baseline nail psoriasis (NAPSI ≥1; N=219; grey) and the subgroup of patients with significant baseline nail psoriasis (NAPSI ≥16 and ≥4 fingernails involved; n=134/219; red). N: number of patients.